Peptide Bio IndexEvidence first. Hype last.
⌕

MOTS-c Benefits, Uses, and Protocols: What Published Research Reports

Written by

in

Benefits & Uses
PBIPeptide Bio Index Editorial DeskSource-labeled research summary
Source-limited12 min readUpdated Sep 3, 2026
Jump to a section
  1. What is MOTS-c?
  2. Why researchers study it
  3. Benefits discussed in literature
  4. Uses discussed in research
  5. Mechanisms discussed in published studies
  6. Reported study designs and protocol examples
  7. Protocol table from cited sources
  8. Limitations and research gaps
  9. Documentation checklist
  10. Related research supplies
  11. More MOTS-c research
  12. Sources and references

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.

Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16–amino‑acid mitochondrial‑derived peptide encoded within the mitochondrial 12S rRNA that has been reported to translocate to the nucleus under metabolic stress and to modulate metabolic and stress‑response pathways; interest in MOTS-c arises from preclinical reports linking it to insulin sensitivity, obesity resistance, antioxidant gene regulation, and potential anti‑tumor effects, but clinical translation remains undeveloped in the reviewed literature (S1, S2, S6).

What is MOTS-c?

MOTS-c is a 16–amino‑acid peptide encoded by a short open reading frame in the mitochondrial 12S rRNA region and classified as a mitochondrial‑derived peptide (MDP) (S1, S2). [S1] [S2]

In response to metabolic stress, MOTS-c has been reported to translocate from mitochondria to the nucleus where it can influence nuclear gene expression; circulating (plasma/serum) levels have been detected and have been reported to decline with age in the reviewed sources (S6, S1). [S6] [S1]

Why researchers study it

Researchers investigate MOTS-c because multiple preclinical studies indicate roles in metabolic homeostasis (including insulin sensitivity and resistance to diet‑induced obesity), mitonuclear signaling, and cellular stress responses—suggesting therapeutic potential for metabolic diseases, aging, cardiovascular injury, and inflammation (S2, S6, S1). [S2] [S6] [S1]

Reviews summarize MOTS-c as part of a broader family of mitochondrial‑encoded peptides with regulatory effects on metabolism, and note interest in its potential to inform new diagnostic markers and therapeutic approaches for metabolic disorders (S7, S1). [S7] [S1]

Benefits discussed in literature

Improved metabolic outcomes: Preclinical studies report that MOTS-c treatment in mice prevented age‑dependent and high‑fat‑diet‑induced insulin resistance and diet‑induced obesity, and that skeletal muscle is a primary target for these metabolic effects (S2). [S2]

Gestational diabetes model findings: In a mouse gestational diabetes mellitus (GDM) model, MOTS-c administration during pregnancy was reported to alleviate hyperglycemia, improve insulin sensitivity and glucose tolerance, reduce offspring birth weight and mortality, increase skeletal muscle insulin sensitivity, elevate glucose uptake in vitro, and protect pancreatic β cells from STZ‑mediated injury (S4). [S4]

Anti‑tumor activity in preclinical models: MOTS-c levels were reported to be reduced in serum and tumor tissues from ovarian cancer patients, and exogenous MOTS-c inhibited proliferation, migration, and invasion of ovarian cancer cells and produced marked anti‑tumor effects in vivo without reported systemic toxicity in the reviewed study (S3). [S3]

Protection against ischemia–reperfusion injury: In rat lung ischemia–reperfusion models, endogenous MOTS-c upregulation in endothelium correlated with barrier preservation and reduced oxidative stress, and exogenous MOTS-c administration attenuated lung injury and mortality while activating antioxidant gene programs (S5). [S5]

Proposed broader physiological effects: Reviews and summaries of the literature describe MOTS-c as having reported or proposed effects on muscle function, bone metabolism, immune regulation, and aging‑related processes, largely via metabolic pathway modulation (S7, S1). [S7] [S1]

Uses discussed in research

Preclinical therapeutic experiments: MOTS-c has been used experimentally in mouse models to probe effects on insulin resistance, obesity, and gestational diabetes, and in rat models for ischemia–reperfusion injury; these are experimental research uses rather than established clinical therapies (S2, S4, S5). [S2] [S4] [S5]

Cancer research applications: Studies have measured MOTS-c in patient samples (serum and tumor tissue) and applied exogenous MOTS-c in cell culture and in vivo tumor models to investigate anti‑tumor mechanisms (S3). [S3]

Cellular stress and gene‑regulation research: MOTS-c has been used in cultured cells under metabolic stress (e.g., glucose restriction) to study mitonuclear communication and transcriptional responses, including ARE‑regulated genes (S6). [S6]

Clinical translation status: Reviews note that MOTS-c has been used less frequently in disease treatment and that, as of the reviewed literature, no effective clinical application or standardized method to apply MOTS-c in patients has been developed (S1). [S1]

Mechanisms discussed in published studies

Nuclear translocation and gene regulation: MOTS-c has been reported to translocate to the nucleus under metabolic stress and to regulate nuclear gene expression in an AMPK‑dependent manner, including regulation of genes bearing antioxidant response elements (AREs) and interaction with ARE‑regulating transcription factors such as NRF2 (NFE2L2) (S6). [S6]

AMPK activation via folate‑purine pathway disruption: Cellular actions of MOTS-c were reported to inhibit the folate cycle and tethered de novo purine biosynthesis, leading to activation of AMPK—mechanisms linked to effects on insulin sensitivity and metabolic homeostasis (S2, S7). [S2] [S7]

Protein interaction and ubiquitination pathways: In ovarian cancer models, MOTS-c was reported to interact with LARS1, promote LARS1 ubiquitination and proteasomal degradation, and to attenuate USP7‑mediated LARS1 deubiquitination by competing with USP7 for LARS1 binding (S3). [S3]

ROS‑CK2A‑MYH9 pathway and antioxidant gene activation: In rat lung ischemia–reperfusion studies, hypoxia–reoxygenation was reported to trigger ROS‑dependent CK2A‑mediated phosphorylation of MYH9, enabling MOTS-c binding to MYH9–γ‑Actin complexes for nuclear transport and direct interaction with promoters of antioxidant genes (e.g., HMOX1, NQO1) (S5). [S5]

Integrated mitonuclear signaling: Reviews and mechanistic studies emphasize that MOTS-c represents a mitochondrial‑encoded factor that contributes to mitonuclear communication and the coordinated regulation of cellular homeostasis under stress (S1, S6). [S1] [S6]

Reported study designs and protocol examples

Mouse metabolic and obesity studies: In published mouse studies MOTS-c was administered experimentally and reported to prevent age‑dependent and high‑fat‑diet‑induced insulin resistance and diet‑induced obesity; specific amounts, routes, and dosing regimens are not reported in the reviewed excerpt (S2). [S2]

Gestational diabetes mouse model example: A GDM model was established by short‑term high‑fat diet combined with low‑dose streptozotocin (STZ) treatment, and MOTS-c was reported as administered daily during pregnancy with outcomes measured for glucose/insulin levels, glucose/insulin tolerance, and reproductive outcomes; the reviewed excerpt does not report amounts or administration routes (S4). [S4]

Cancer research designs: Clinical sample analyses reported reduced MOTS-c in serum and tumor tissue from ovarian cancer patients, and exogenous MOTS-c was applied in vitro and in vivo to assess effects on cell proliferation, migration, invasion, cell cycle, apoptosis, and tumor growth; specific dosing details are not reported in the reviewed excerpt (S3). [S3]

Ischemia–reperfusion and biomarker studies: Rat LIRI models were used to evaluate endogenous MOTS-c dynamics and to test exogenous MOTS-c for effects on oxidative injury, inflammation, and survival; the study also reported clinical measurement of serum MOTS-c changes within 24 hours after cardiopulmonary bypass and assessed predictive performance for ARDS, but the reviewed excerpt does not provide administered doses or routes (S5). [S5]

Cellular mechanistic studies: In vitro studies under glucose restriction and metabolic stress used MOTS-c to investigate nuclear translocation and regulation of ARE‑bearing genes and interaction with stress‑responsive transcription factors; specific experimental concentrations or exposure durations are not reported in the reviewed excerpt (S6). [S6]

Protocol table from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Source Study Type Model / Subject Amount Reported Route Reported Frequency Duration Notes
[S2] Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't mice not reported in the reviewed source. not reported in the reviewed source. not reported in the reviewed source. not reported in the reviewed source. MOTS-c treatment in mice was reported to prevent age‑dependent and high‑fat diet‑induced insulin resistance and diet‑induced obesity; primary target organ reported as skeletal muscle and mechanism linked to inhibition of the folate cycle and AMPK activation (S2).
[S4] Journal Article, Research Support, Non-U.S. Gov't mouse gestational diabetes mellitus (GDM) model (HFD + low‑dose STZ) not reported in the reviewed source. not reported in the reviewed source. administered daily during pregnancy (reported in the reviewed source). during pregnancy (reported in the reviewed source). MOTS-c administration during pregnancy was reported to alleviate hyperglycemia, improve insulin sensitivity and glucose tolerance, reduce birth weight and offspring death, increase skeletal muscle insulin sensitivity and glucose uptake in vitro, and protect pancreatic β cells from STZ injury (S4).
[S3] Journal Article, Research Support, Non-U.S. Gov't ovarian cancer: human patient serum/tumor measurements; in vitro OC cell lines and in vivo tumor models not reported in the reviewed source. not reported in the reviewed source. not reported in the reviewed source. not reported in the reviewed source. MOTS-c levels were reported reduced in serum and tumor tissues from OC patients; exogenous MOTS-c inhibited OC cell proliferation, migration, and invasion, induced cell cycle arrest and apoptosis, and showed anti‑tumor effects in vivo with no systemic toxicity reported in the reviewed excerpt (S3).
[S5] Journal Article, Research Support, Non-U.S. Gov't rat lung ischemia–reperfusion injury (LIRI) models; clinical serum measurements post‑CPB not reported in the reviewed source. not reported in the reviewed source. not reported in the reviewed source. not reported in the reviewed source. Endothelial MOTS-c upregulation correlated with barrier preservation and reduced oxidative stress; exogenous MOTS-c administration in rats attenuated lung injury, and clinical serum ΔMOTS-c within 24 h post‑CPB was reported as a predictor of ARDS incidence (S5).
[S6] Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't cell culture models under metabolic stress (e.g., glucose restriction) not reported in the reviewed source. not applicable (in vitro cell studies); not reported in the reviewed source. not reported in the reviewed source. not reported in the reviewed source. MOTS-c translocation to the nucleus and regulation of nuclear gene expression in response to metabolic stress was reported to be AMPK dependent and to include regulation of ARE‑bearing genes and interaction with NRF2 (S6).

Limitations and research gaps

  • Most of the reviewed studies are preclinical (cellular and animal models); direct clinical evidence of safety and efficacy in humans is limited or not reported in the reviewed sources (S1, S8).
  • Detailed protocol parameters (administration amount, route, and most dosing schedules) are not reported in the provided excerpts and therefore are not summarized here; where not available the entry is listed as “not reported in the reviewed source.”
  • Heterogeneity across models (cell types, mouse models, rat models, cancer types) limits straightforward generalization of outcomes between studies (S2, S3, S5).
  • Review articles note conceptual and mechanistic promise but also emphasize that translational and clinical development pathways for MOTS-c remain to be established (S1, S7).
  • Safety data in humans are not provided in the reviewed excerpts; one narrative review highlights scarce rigorous human safety data for many peptides marketed outside regulatory oversight (S8).

Documentation checklist

  • Confirm species and model used in each primary study (mouse, rat, cell culture, patient samples).
  • Refer to the original full‑text articles for experimental dosing, administration routes, and full methods before attempting replication or interpretation.
  • Verify current regulatory status and approvals for peptide research use in your jurisdiction.
  • Evaluate whether mechanistic findings (e.g., AMPK activation, nuclear translocation) are replicated across independent studies.
  • Prioritize peer‑reviewed primary sources for protocol details and safety data rather than summary excerpts.
  • Ultra‑low‑temperature laboratory freezer (for peptide storage documentation and organization)
  • Labeled cryovials and inventory labels for sample tracking
  • Protein‑grade microcentrifuge tubes and rack organization systems
  • Laboratory notebook templates or electronic lab notebook (ELN) entries for protocol documentation
  • Surface and equipment cleaning supplies compatible with laboratory environments (e.g., DNA/RNA/protein‑decontamination wipes)

Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Compact vial organization

Leng Ke 10-Slot Clear Vial Case

A transparent 10-slot organizer sized for compatible 1–3 mL glass vials. Confirm vial dimensions and documented storage requirements before selection.

View on Amazon (paid link)

Electronics and screen care

iCloth 70% IPA Electronics Wipes

Lint-free wipes marketed for compatible screens and electronics, useful in documentation and equipment work areas.

View on Amazon (paid link)

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.

More MOTS-c research

Sources and references

  1. [S1] Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.. Frontiers in endocrinology. 2023. PMID: 36761202. DOI: 10.3389/fendo.2023.1120533
  2. [S2] Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.. Cell metabolism. 2015. PMID: 25738459. DOI: 10.1016/j.cmet.2015.02.009
  3. [S3] Yin Y, Li Y, Ma B, Ren C, Zhao S, Li J. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024. PMID: 39321430. DOI: 10.1002/advs.202405620
  4. [S4] Yin Y, Pan Y, He J, Zhong H, Wu Y, Ji C. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.. Pharmacological research. 2022. PMID: 34798268. DOI: 10.1016/j.phrs.2021.105987
  5. [S5] Li X, Zhan F, Qiu G, Lu P, Shen Z, Qi Y. MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.. Redox biology. 2025. PMID: 40403491. DOI: 10.1016/j.redox.2025.103681
  6. [S6] Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.. Cell metabolism. 2018. PMID: 29983246. DOI: 10.1016/j.cmet.2018.06.008
  7. [S7] Gao Y, Wei X, Wei P, Lu H, Zhong L, Tan J. MOTS-c Functionally Prevents Metabolic Disorders.. Metabolites. 2023. PMID: 36677050. DOI: 10.3390/metabo13010125
  8. [S8] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.

More posts